Abbvie Inc
NYSE:ABBV
Abbvie Inc
Cash Interest Paid
Abbvie Inc
Cash Interest Paid Peer Comparison
Competitive Cash Interest Paid Analysis
Latest Figures & CAGR of Competitors
Company | Cash Interest Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Abbvie Inc
NYSE:ABBV
|
Cash Interest Paid
$2.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash Interest Paid
$891m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
14%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash Interest Paid
$2.4B
|
CAGR 3-Years
26%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
Moderna Inc
NASDAQ:MRNA
|
Cash Interest Paid
$39m
|
CAGR 3-Years
63%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash Interest Paid
$43.1m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
15%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash Interest Paid
$73.1m
|
CAGR 3-Years
47%
|
CAGR 5-Years
27%
|
CAGR 10-Years
12%
|
See Also
What is Abbvie Inc's Cash Interest Paid?
Cash Interest Paid
2.5B
USD
Based on the financial report for Dec 31, 2023, Abbvie Inc's Cash Interest Paid amounts to 2.5B USD.
What is Abbvie Inc's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 5Y
15%
Over the last year, the Cash Interest Paid growth was -3%. The average annual Cash Interest Paid growth rates for Abbvie Inc have been -2% over the past three years , 15% over the past five years .